1. Home
  2. FBGL vs PHGE Comparison

FBGL vs PHGE Comparison

Compare FBGL & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FBGL

FBS Global Limited Ordinary Shares

BUY

Current Price

$0.84

Market Cap

11.3M

ML Signal

BUY

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$5.86

Market Cap

9.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBGL
PHGE
Founded
1996
2015
Country
Singapore
Israel
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.3M
9.5M
IPO Year
2025
N/A

Fundamental Metrics

Financial Performance
Metric
FBGL
PHGE
Price
$0.84
$5.86
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$26.00
AVG Volume (30 Days)
2.9M
2.1M
Earning Date
10-17-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,491,303.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.41
$1.50
52 Week High
$5.45
$22.06

Technical Indicators

Market Signals
Indicator
FBGL
PHGE
Relative Strength Index (RSI) 48.66 62.46
Support Level $0.78 $5.62
Resistance Level $0.90 $8.50
Average True Range (ATR) 0.08 1.05
MACD -0.01 0.26
Stochastic Oscillator 53.65 54.66

Price Performance

Historical Comparison
FBGL
PHGE

About FBGL FBS Global Limited Ordinary Shares

FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and Sales of construction materials.

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Share on Social Networks: